Which has better earnings & valuation, TMDX or GKOS?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $635.89M 3.94 $190.29M $4.40 16.46 Glaukos $507.44M 14.12 -$187.69M -$3.28 N/A

Does the media refer more to TMDX or GKOS?

In the previous week, Glaukos had 1 more articles in the media than TransMedics Group. MarketBeat recorded 3 mentions for Glaukos and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Glaukos' score of 0.16 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TMDX or BLCO?

In the previous week, Bausch + Lomb had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Bausch + Lomb and 2 mentions for TransMedics Group. Bausch + Lomb's average media sentiment score of 0.60 beat TransMedics Group's score of 0.25 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TMDX or STVN?

TransMedics Group presently has a consensus target price of $134.00, indicating a potential upside of 85.02%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.46 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media favor TMDX or STVN?

In the previous week, Stevanato Group had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Stevanato Group and 2 mentions for TransMedics Group. Stevanato Group's average media sentiment score of 0.57 beat TransMedics Group's score of 0.25 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or TMDX?

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $288.07M 19.63 -$68.92M $0.14 454.10 TransMedics Group $635.89M 3.94 $190.29M $4.40 16.46

Does the media prefer LQDA or TMDX?

In the previous week, Liquidia had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Liquidia and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Liquidia's score of -0.12 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TransMedics Group (TMDX) Competitors

$72.42 +1.05 (+1.48%)

As of 09:47 AM Eastern

Compare

TMDX vs. GKOS, BLCO, STVN, LQDA, and LIVN

Should you buy TransMedics Group stock or one of its competitors? MarketBeat compares TransMedics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransMedics Group include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does TransMedics Group compare to Glaukos?

TransMedics Group (NASDAQ:TMDX) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

TransMedics Group has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

TransMedics Group has a net margin of 27.04% compared to Glaukos' net margin of -34.34%. TransMedics Group's return on equity of 22.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Glaukos	-34.34%	-6.92%	-5.25%

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TransMedics Group currently has a consensus target price of $134.00, suggesting a potential upside of 85.02%. Glaukos has a consensus target price of $146.17, suggesting a potential upside of 19.83%. Given TransMedics Group's higher probable upside, analysts clearly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Glaukos had 1 more articles in the media than TransMedics Group. MarketBeat recorded 3 mentions for Glaukos and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Glaukos' score of 0.16 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.94	$190.29M	$4.40	16.46
Glaukos	$507.44M	14.12	-$187.69M	-$3.28	N/A

Summary

TransMedics Group beats Glaukos on 12 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Bausch + Lomb?

TransMedics Group (NASDAQ:TMDX) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

TransMedics Group has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Bausch + Lomb had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Bausch + Lomb and 2 mentions for TransMedics Group. Bausch + Lomb's average media sentiment score of 0.60 beat TransMedics Group's score of 0.25 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.94	$190.29M	$4.40	16.46
Bausch + Lomb	$5.10B	1.08	-$360M	-$0.62	N/A

TransMedics Group currently has a consensus price target of $134.00, indicating a potential upside of 85.02%. Bausch + Lomb has a consensus price target of $17.92, indicating a potential upside of 16.33%. Given TransMedics Group's stronger consensus rating and higher probable upside, research analysts plainly believe TransMedics Group is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

TransMedics Group has a net margin of 27.04% compared to Bausch + Lomb's net margin of -4.21%. TransMedics Group's return on equity of 22.38% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Bausch + Lomb	-4.21%	3.60%	1.69%

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TransMedics Group beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Stevanato Group?

TransMedics Group (NASDAQ:TMDX) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

TransMedics Group has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

TransMedics Group has a net margin of 27.04% compared to Stevanato Group's net margin of 11.76%. TransMedics Group's return on equity of 22.38% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Stevanato Group	11.76%	10.27%	6.08%

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Stevanato Group had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Stevanato Group and 2 mentions for TransMedics Group. Stevanato Group's average media sentiment score of 0.57 beat TransMedics Group's score of 0.25 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group presently has a consensus target price of $134.00, indicating a potential upside of 85.02%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

TransMedics Group has higher earnings, but lower revenue than Stevanato Group. TransMedics Group is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.94	$190.29M	$4.40	16.46
Stevanato Group	€1.34B	4.32	€158.21M	€0.59	32.41

Summary

TransMedics Group beats Stevanato Group on 10 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Liquidia?

Liquidia (NASDAQ:LQDA) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Liquidia currently has a consensus price target of $54.50, suggesting a potential downside of 14.27%. TransMedics Group has a consensus price target of $134.00, suggesting a potential upside of 85.02%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has a net margin of 27.04% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
TransMedics Group	27.04%	22.38%	8.46%

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$288.07M	19.63	-$68.92M	$0.14	454.10
TransMedics Group	$635.89M	3.94	$190.29M	$4.40	16.46

Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

In the previous week, Liquidia had 3 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for Liquidia and 2 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Liquidia's score of -0.12 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Liquidia on 9 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to LivaNova?

TransMedics Group (NASDAQ:TMDX) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

TransMedics Group presently has a consensus target price of $134.00, suggesting a potential upside of 85.02%. LivaNova has a consensus target price of $79.38, suggesting a potential upside of 6.59%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

TransMedics Group has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to LivaNova's net margin of 7.48%. TransMedics Group's return on equity of 22.38% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
LivaNova	7.48%	16.48%	7.59%

TransMedics Group has higher earnings, but lower revenue than LivaNova. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.94	$190.29M	$4.40	16.46
LivaNova	$1.43B	2.85	-$242.47M	$1.95	38.19

In the previous week, TransMedics Group had 2 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for TransMedics Group and 0 mentions for LivaNova. LivaNova's average media sentiment score of 1.87 beat TransMedics Group's score of 0.25 indicating that LivaNova is being referred to more favorably in the news media.

Company	Overall Sentiment
TransMedics Group	Neutral
LivaNova	Very Positive

Summary

TransMedics Group beats LivaNova on 11 of the 15 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDX vs. The Competition

Export

Metric	TransMedics Group	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.51B	$7.30B	$6.32B	$12.38B
Dividend Yield	N/A	1.23%	2.69%	5.31%
P/E Ratio	16.49	46.43	23.73	24.35
Price / Sales	3.94	47.52	498.78	95.26
Price / Cash	17.75	24.16	41.39	55.53
Price / Book	5.25	7.30	9.96	6.72
Net Income	$190.29M	$159.22M	$3.56B	$337.03M
7 Day Performance	7.77%	1.02%	-1.04%	-0.16%
1 Month Performance	-23.71%	6.48%	2.18%	3.74%
1 Year Performance	-46.59%	3.53%	28.93%	34.34%

TransMedics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDX TransMedics Group	4.5028 of 5 stars	$72.42 +1.5%	$134.00 +85.0%	-45.0%	$2.51B	$635.89M	16.49	210
GKOS Glaukos	2.5399 of 5 stars	$120.95 +0.6%	$146.17 +20.8%	+33.8%	$7.10B	$551.35M	N/A	1,094	Gap Up High Trading Volume
BLCO Bausch + Lomb	4.6641 of 5 stars	$15.95 +0.2%	$18.08 +13.4%	+33.5%	$5.69B	$5.10B	N/A	13,000	Analyst Forecast
STVN Stevanato Group	2.1042 of 5 stars	€18.12 +0.6%	N/A	-17.0%	€5.49B	€1.20B	30.72	6,010	Analyst Forecast
LQDA Liquidia	2.233 of 5 stars	$60.98 flat	$49.33 -19.1%	+254.1%	$5.42B	$158.32M	435.60	50	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, BLCO, STVN, LQDA, and LIVN

How does TransMedics Group compare to Glaukos?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Summary

How does TransMedics Group compare to Stevanato Group?

Summary

How does TransMedics Group compare to Liquidia?

Summary

How does TransMedics Group compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, BLCO, STVN, LQDA, and LIVN

How does TransMedics Group compare to Glaukos?

Which has more risk and volatility, TMDX or GKOS?

Is TMDX or GKOS more profitable?

Do institutionals & insiders have more ownership in TMDX or GKOS?

Do analysts rate TMDX or GKOS?

Does the media refer more to TMDX or GKOS?

Which has better earnings & valuation, TMDX or GKOS?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Which has more risk & volatility, TMDX or BLCO?

Does the media favor TMDX or BLCO?

Which has stronger earnings & valuation, TMDX or BLCO?

Do analysts recommend TMDX or BLCO?

Is TMDX or BLCO more profitable?

Do institutionals and insiders have more ownership in TMDX or BLCO?

Summary

How does TransMedics Group compare to Stevanato Group?

Which has more volatility & risk, TMDX or STVN?

Is TMDX or STVN more profitable?

Do insiders and institutionals have more ownership in TMDX or STVN?

Does the media favor TMDX or STVN?

Do analysts recommend TMDX or STVN?

Which has better earnings and valuation, TMDX or STVN?

Summary

How does TransMedics Group compare to Liquidia?

Do analysts prefer LQDA or TMDX?

Is LQDA or TMDX more profitable?

Which has better earnings and valuation, LQDA or TMDX?

Which has more risk & volatility, LQDA or TMDX?

Does the media prefer LQDA or TMDX?

Do institutionals & insiders hold more shares of LQDA or TMDX?

Summary

How does TransMedics Group compare to LivaNova?

Do analysts prefer TMDX or LIVN?

Which has more volatility & risk, TMDX or LIVN?

Do institutionals and insiders hold more shares of TMDX or LIVN?

Is TMDX or LIVN more profitable?

Which has higher valuation and earnings, TMDX or LIVN?

Does the media prefer TMDX or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools